Condition: RAS Mutation · Ras (Kras or Nras) Gene Mutation · Colorectal Cancer Recurrent · Sponsor: N.N. Petrov National Medical Research Center of Oncology
There is a huge variety of nucleotide substitutions that activate RAS. The search for new "universal" drugs for the RAS pathway that either interfere with RAS upregulation upstream in the signaling pathway or offset the consequences of RAS activation is important for improving therapeutic outcomes for patients with refractory malignancies. The use of leflunomide or the combination of MEK inhibitor + hydroxychloroquine ± bevacizumab is promising for patients with mutations in RAS cascade genes who have failed all existing treatment standards.
This description comes directly from the study's public registry record.
Evgeny Imyanitov · +79013023707 · evgeny@imyanitov.spb.ru
Liliya Baboshkina · +79869932745 · lilya_baboshkina@mail.ru
Always discuss trial participation with your own doctor first.
| Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint Petersburg, Russian Federation | Saint Petersburg, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06229340